Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225503404> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4225503404 abstract "The clinical care strategy in Crohn's disease has evolved over time to emphasise a treat-to-target approach in which treatment effectiveness is determined using specific objective treatment goals, in particular healing of the intestinal mucosa on endoscopy. 1 Colombel J-F Narula N Peyrin-Biroulet L Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017; 152: 351-361 Google Scholar The STRIDE-II initiative of the International Organisation∼ for the Study of Inflammatory Bowel Disease defined clinical and endoscopic remission as ultimate targets for Crohn's disease and recommended regular assessment of short-term and intermediate-term targets to adjust therapy for tight control of inflammation. 2 Turner D Ricciuto A Lewis A et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160: 1570-1583 Google Scholar In The Lancet Gastroenterology & Hepatology, Silvio Danese and colleagues report the findings of the STARDUST trial, the first prospective study analysing a treat-to-target strategy in Crohn's disease with ustekinumab. 3 Danese S Vermeire S D'Haens G et al. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022; (published online Feb 1.)https://doi.org/10.1016/S2468-1253(21)00474-X Google Scholar Patients in the treat-to-target arm received ustekinumab as standard induction therapy and then escalated based on endoscopic response at week 16, with further dose optimisation based on clinical symptoms combined with biomarkers (C-reactive protein [CRP] or faecal calprotectin). This was compared with a standard-of-care approach where escalation was based on clinical judgement. At week 48, there was no significant difference between groups in terms of the primary endpoint of endoscopic response, nor for most of the secondary endpoints. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialTimely escalation of ustekinumab therapy for patients with Crohn's disease, based on early endoscopic response, clinical symptoms, and biomarkers, did not result in significantly better endoscopic outcomes at week 48 than symptom-driven decisions alone. Future studies need to confirm if some subgroups of patient might benefit from a treat-to-target strategy with ustekinumab. Full-Text PDF" @default.
- W4225503404 created "2022-05-05" @default.
- W4225503404 creator A5015470174 @default.
- W4225503404 creator A5033087694 @default.
- W4225503404 date "2022-02-01" @default.
- W4225503404 modified "2023-10-16" @default.
- W4225503404 title "Treat to target with ustekinumab for Crohn's disease" @default.
- W4225503404 cites W2528277214 @default.
- W4225503404 cites W2766230215 @default.
- W4225503404 cites W2798086101 @default.
- W4225503404 cites W3115410759 @default.
- W4225503404 cites W3205367234 @default.
- W4225503404 cites W3206303313 @default.
- W4225503404 cites W4226397957 @default.
- W4225503404 doi "https://doi.org/10.1016/s2468-1253(22)00019-x" @default.
- W4225503404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35120657" @default.
- W4225503404 hasPublicationYear "2022" @default.
- W4225503404 type Work @default.
- W4225503404 citedByCount "0" @default.
- W4225503404 crossrefType "journal-article" @default.
- W4225503404 hasAuthorship W4225503404A5015470174 @default.
- W4225503404 hasAuthorship W4225503404A5033087694 @default.
- W4225503404 hasConcept C126322002 @default.
- W4225503404 hasConcept C2778260677 @default.
- W4225503404 hasConcept C2778975655 @default.
- W4225503404 hasConcept C2779134260 @default.
- W4225503404 hasConcept C2779280984 @default.
- W4225503404 hasConcept C2780132546 @default.
- W4225503404 hasConcept C41260117 @default.
- W4225503404 hasConcept C535046627 @default.
- W4225503404 hasConcept C71924100 @default.
- W4225503404 hasConcept C90924648 @default.
- W4225503404 hasConceptScore W4225503404C126322002 @default.
- W4225503404 hasConceptScore W4225503404C2778260677 @default.
- W4225503404 hasConceptScore W4225503404C2778975655 @default.
- W4225503404 hasConceptScore W4225503404C2779134260 @default.
- W4225503404 hasConceptScore W4225503404C2779280984 @default.
- W4225503404 hasConceptScore W4225503404C2780132546 @default.
- W4225503404 hasConceptScore W4225503404C41260117 @default.
- W4225503404 hasConceptScore W4225503404C535046627 @default.
- W4225503404 hasConceptScore W4225503404C71924100 @default.
- W4225503404 hasConceptScore W4225503404C90924648 @default.
- W4225503404 hasLocation W42255034041 @default.
- W4225503404 hasLocation W42255034042 @default.
- W4225503404 hasOpenAccess W4225503404 @default.
- W4225503404 hasPrimaryLocation W42255034041 @default.
- W4225503404 hasRelatedWork W1989592602 @default.
- W4225503404 hasRelatedWork W2317479536 @default.
- W4225503404 hasRelatedWork W2328449109 @default.
- W4225503404 hasRelatedWork W2914039486 @default.
- W4225503404 hasRelatedWork W2914372963 @default.
- W4225503404 hasRelatedWork W3088583663 @default.
- W4225503404 hasRelatedWork W3095546853 @default.
- W4225503404 hasRelatedWork W3180072626 @default.
- W4225503404 hasRelatedWork W4282983262 @default.
- W4225503404 hasRelatedWork W4376102407 @default.
- W4225503404 isParatext "false" @default.
- W4225503404 isRetracted "false" @default.
- W4225503404 workType "article" @default.